Table 2.
Expression of MAGED4B and FJX1 in: (A) HNSCC and (B) 5 most common cancers worldwide (breast, colon, lung, prostate and rectal cancers).
| HNSCC | MAGED4B | FJX1 | MAGED4B and/or FJX1 | MAGED4B and FJX1 | Both negative |
|---|---|---|---|---|---|
| A | |||||
| Stage I (n = 15) | 15 (100.0%) | 14 (93.3%) | 15 (100.0%) | 14 (93.3%) | 0 (0.0%) |
| Stage II (n = 22) | 22 (100.0%) | 20 (90.9%) | 22 (100.0%) | 20 (90.9%) | 0 (0.0%) |
| Stage III (n = 15) | 15 (100.0%) | 14 (93.3%) | 15 (100.0%) | 14 (93.3%) | 0 (0.0%) |
| Stage IV (n = 15) | 14 (93.3%) | 14 (93.3%) | 14 (93.3%) | 14 (93.3%) | 1 (6.7%) |
| Unknown stage (n = 30) | 26 (86.7%) | 25 (83.3%) | 26 (86.7%) | 25 (83.3%) | 4 (13.3%) |
| Total (n = 97) |
92 (94.8%) |
87 (89.7%) |
92 (94.8%) |
87 (89.7%) |
5 (5.2%) |
| Cancer type |
MAGED4B |
FJX1 |
MAGED4B and/or FJX1 |
MAGED4B and FJX1 |
Both negative |
| B | |||||
| Breast | 41/41(100.0%) | 36/41 (87.8%) | 41/41 (100.0%) | 36/41 (87.8%) | 0/41 (0.0%) |
| Colon | 25/30 (83.3%) | 15/30 (50.0%) | 27/29 (93.1%) | 11/29 (37.9%) | 2/29 (6.9%) |
| Lung | 42/42 (100.0%) | 37/48 (77.1%) | 42/42 (100.0%) | 32/42 (76.2%) | 0/42 (0.0%) |
| Prostate | 34/42 (81.0%) | 37/44 (84.1%) | 38/40 (95.0%) | 29/40 (72.5%) | 2/40 (5.0%) |
| Rectal | 13/16 (81.2%) | 12/14 (85.7%) | 13/14 (92.9%) | 11/14 (78.6%) | 1/14 (7.1%) |
| Total | 155/171 (90.6%) |
137/177 (77.4%) |
161/166 (97.0%) |
119/166 (71.7%) |
5/166 (3.0%) |